Immunostimulating therapy and prevention of acute respiratory viral infections in children

Acute respiratory infections (ARIs) have been holding leading positions in terms of prevalence rates in all age groups for much longer than one year, accounting for more than 70%. World Health Organization experts note that ARI is the most common group of diseases in the human population. Back in 1995, D.J. Rowlands stated in his publication that the average person has ARI for a total of about two years during his life. The published report “On the state of the sanitary and epidemic well-being of the population in the Russian Federation, 2017” showed that the acute respiratory viral infection (ARVI) and influenza rate has increased by 9.3% over the past 6 years, more than 20% of the population have ARVI annually and children of younger age groups account for 70–80% among them. The annual economic damage from the burden of influenza and SARS is estimated at more than 500 billion roubles. The use of drugs that can prevent the spread of ARI, prevent attachment of secondary bacterial infections, reduce the need for prescribing systemic antibacterial drugs will allow to reduce the antibiotic resistance in microbes. However, the existing medicinal products are mainly represented by vaccines and antiviral drugs against influenza in almost complete absence of drugs against other ARI pathogens. In 2013, the World Health Organization launched the BRaVE initiative to expand treatment options for ARVI with the development of effective antivirals against the most significant pathogens and/or safe and effective biological response modifiers.
The article is devoted to the challenge of treatment and prevention of ARI in children, the therapeutic potential of a plant preparation containing aloe extract. The data presented in the clinical results review of the use of this drug prove the feasibility and safety of its introduction in the ARI treatment and prevention regimens in children.

1. Gliadelova N.P., Marushko T.V., Romankevich I.V. Experience of Bioaron C usage for prevention and treatment of acute respiratory diseases in children (literature review). Sovremennaya Pediatriya. 2017;(6):106–112. (In Russ.) https://doi.org/10.15574/SP.2017.86.106.

2. Okhotnikova E.N., Rudenko S.N., Kolomiets E.N. Recurrent respiratory tract infections in children and their immunoprophylaxis in the terms of the modern ideas about the immunomodulatory activity of immunotropic preparations. Sovremennaya Pediatriya. 2013;(1):42–50. (In Russ.) Available at: https://med-expert.com.ua/journals/wp-content/uploads/2017/06/sp_01_2013.pdf.

3. AlKhater S.A. Approach to the child with recurrent infections. J Family Community Med. 2009;16(3):77–82. Available at: https://www.jfcmonline. com/article.asp?issn=2230-8229;year=2009;volume=16;issue=3;spage=77;epage=82;aulast=AlKhater.

4. Dronov I.A., Shatalina S.I. The role of symptomatic therapy of respiratory infections in children in preventing and overcoming drug resistance of microorganisms. Farmateka. 2017;(11):46–51. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/35241.

5. Yartsev M.N., Chuvirov D.G. Clinical efficacy of Bioaron C in children suffering from frequently recurrent and bacterial infections of the upper respiratory tract. News of Medicine and Pharmacy. 2012;435. (In Russ.) Available at: http://www.mif-ua.com/archive/article/34460.

6. Kvashnina L.V., Matvienko I.N. Recurrent respiratory infections in children: is prevention possible? Paediatrics Eastern Europe. 2016;4(4):591–603. (In Russ.) Available at: https://resistol.com.ua/wp-content/uploads/2019/01/Стаття-№3_Резістол_Матвієнко_2016.pdf.

7. Avdeeva E.V., Kurkin V.A. Immunomodulating drugs: supply and demand. Remedium. 2007;(3):26–28. (In Russ.) Available at: https://elibrary.ru/item.asp?id=9956257.

8. Korsun V.F., Korsun E.V., Zakharov P.A. Organization of phytotherapy in social protection centers. Moscow: Institute of Phytotherapy; 2011. 42 p. (In Russ.)

9. Abaturov A.E. Phytotherapy in the treatment and prevention of acute respiratory diseases in children. Medical Nature. 2011;(7):56–59. (In Russ.) Available at: https://health-ua.com/pics/pdf/Mn_7-11/56-59.pdf.

10. Barnaulov O.D. Phytotherapy of patients with bronchopulmonary diseases. St Petersburg: N-L; 2008. 304 p. (In Russ.)

11. T’Hart L.A., van den Berg A.J., Kuis L., van Dijk H., Labadie R.P. An anti-complementary polysaccharide with immunological adjuvant activity from the leaf parenchyma gel of Aloe vera. Planta Med. 1989;55(6):509–512. https://doi.org/10.1055/s-2006-962082.

12. Glushchenko S.N., Shmygareva A.A. Development of methods of standardization of phytopreparation based on aloe arborescens and aloe vera. In: Kurkin V.A. (ed.). Modern problems of pharmacognosy: a collection of materials of the IV Interuniversity scientific and practical conference with international participation. Samara: Samara State Medical University; 2019, pp. 119–125. (In Russ.) Available at: https://elibrary.ru/item.asp?id=42939276&pff=1.

13. Glatthaar-Saalmüller B., Michalak A., Bastian P., Fal A.M. In vitro evaluation of antiviral activity of biostymina and bioaron c against human pathogenic virus: rhinovirus type 14 (HRV14). Postępy Fitoterapii. 2012;(3):156–161. (In Polish) Available at: http://www.czytelniamedyczna.pl/4191,ocenaaktywnoci-przeciwwirusowej-in-vitro-preparatlw-biostymina-i-bioaron-cwzgl.html.

14. Demkow U., Skopińska-Różewska E.E. Wpływ preparatu Bioaron C na odporność. Warszawa: Medyk; 2003, s. 51–56.

15. Glyadelova N.P. Evaluation of clinical efficacy and safety of using the drug “Bioaron С” with outpatient treatment of acute respiratory infections in children. Sovremennaya Pediatriya. 2016;(1):82–86. (In Russ.) https://doi.org/10.15574/SP.2016.73.82.

16. Glyadelova N.P., Unich N.K., Orlyuk I.B. Plant immunomodulator Bioaron S: experience of application for the prevention and treatment of infectious diseases of the upper respiratory tract in children. Sovremennaya Pediatriya. 2011;(1):130–134. (In Russ.) Available at: https://med-expert.com.ua/journals/wp-content/uploads/2017/06/sp_01_2011_web.pdf.

17. Plaskett B.A. Aloe against infection. Biomedical information services LTD. 1996;(9). Available at: https://www.yumpu.com/en/document/read/48754340/aloe-vera-the-health-benefits-tiverton-devon-uk-desert-harvest.

18. Fal A.M., Schönknecht K., Jambor J. Immunomodulatory role of Biostymina® and Bioaron® C in the prevention and treatment of upper respiratory tract infections. Wiadomości Lekarskie. 2016;LXIX(1, cz. II):72–79 (In Polish) Available at: https://www.researchgate.net/publication/311771582_Immunomodulatory_role_of_BiostyminaR_and_BioaronR_C_in_the_prevention_and_treatment_of_upper_respiratory_tract_infections.

19. Smirnova M.O., Ruzhitskaya E.A., Vinogradova T.V., Pampura A.N. efficiency and safety of Bioaron C in frequently ill children. Russian Bulletin of Perinatology and Pediatrics. 2010;55(1):113–116. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=15264798.

20. Cichocki M., Michalak A., Appel K. Anti-inflammatory properties of Aloe Arborescens and Aronia Melanicarpa preparation Bioaron C. 47th Congress of the Polish Biochemical Society, Polihs¬German Biochemical Societies Joint Meeting Poznań, Poland, 11–14 September 2012. Poznań; 2012, p. 196.

21. Horoszkiewicz-Hassan M., Beuscher N., Lehnfeld R., Theib U., Pfarr E. Tolerability and efficacy of Bioaron C® syrup in the treatment of upper respiratory tract infection in children. Results of a post-marketing surveillance study in Poland. Herba Polonica. 2005;51(1–2):45–53. Available at: https://eurekamag.com/research/004/486/004486492.php.

22. Snegotskaya M.N., Konopelko O.Yu. On the effectiveness of the use of the drug Bioaron C® for the prevention and treatment of ARI. Paediatrician Practice. 2009;(5):22–26. (In Russ.) Available at: https://medi.ru/info/4522/.

23. Lokshina E.E., Zaitseva O.V. New approaches in the treatment of recurrent respiratory infections in children. Pediatrics. Consilium Medicum. 2009;(4):20–24. (In Russ.) Available at: https://medi.ru/info/3068/.

24. Aryaev N.L., Starikova A.A., Pivak O.E. Evaluation of the clinical efficacy of the use of the drug “Bioaron C” in outpatient treatment and prevention of recurrent respiratory infections in children. Sovremennaya Pediatriya. 2010;(5):64–67. (In Russ.) Available at: https://med-expert.com.ua/journals/wp-content/uploads/2017/06/sp_05_2010_web.pdf.

25. Prokhorov E.V., Ostrovskiy I.M., Belskaya E.A., Tolstikova E.A., Khodanich N.A., Khilinskaya I.A. The effectiveness of using Bioaron C in the treatment of acute and recurrent bronchitis in children. Sovremennaya Pediatriya. 2011;(3):81–85. (In Russ.) Available at: https://med-expert.com.ua/journals/wp-content/uploads/2017/06/sp_3_2011_ok.pdf.

26. Fal A.M., Michalak A. Bioaron C w leczeniu zakażeń górnych dróg oddechowych u dzieci: wpływ na przebieg zakażenia. Wiadomości Lekarskie. 2013;LXVI(4, cz. II):340–345. Available at: http://zanotowane.pl/916/7340/.

27. Konova O.M., Dmitrienko E.G., Davydova I.V. Frequently ill children. Physiotherapist’s view. Pediatric Pharmacology. 2012;9(6):95–98. (In Russ.) https://doi.org/10.15690/pf.v9i6.525.

28. Davydova I.V. Cough phytotherapy in early childhood. Pediatric Pharmacology. 2012;9(2):107–109. https://doi.org/10.15690/pf.v9i2.257.

29. Bogomilsky M.R., Radtsig E.Yu., Kotova E.N., Ermilova N.V. Local therapy for laryngopharyngeal infl ammatory diseases in children. Vestnik Oto-RinoLaringologii. 2010;(2):63–65. (In Russ.) Available at: https://www.mediasphera.ru/scripts/secure/file.php?TYPE=ISSUE&ID=79015&LANG=RU.